Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated May 18, 2017 (9 years ago)

Levophed norepinephrine bitartrate

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

GMP Deviation; A foreign stopper was observed during packaging of a lot of product.

Cause type: Packaging defect

Failed child-resistant closures, leaks, cracked containers, or a defective delivery device. Packaging failures risk accidental exposure (especially to children) or product contamination. All packaging defect recalls.

What was recalled

Levophed norepinephrine bitartrate, injection, USP, 4 mg /4 mL (1 mg/mL),Rx only, Hospira, Inc. Lake Forest, IL --- NDC 0409-3375-04

Affected NDC 0409-3375-04

Compare with the code on your package — it is the most precise check available.

Drug: Epinephrine

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Levophed
Norepinephrine Bitartrate
NDC 00409-3375
1 mg/mL Injection, Solution, Concentrate
Intravenous
Hospira, Inc. Rx
Recalling firm
Hospira Inc., A Pfizer Company
NDC code
0409-3375-04
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0898-2017 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Epinephrine recalls

See all
Class I · High risk

Epinephrine Injection

Presence of Particulate Matter and Lack of Assurance of Sterility. Particulate matter identified as nylon, cellulosic, acrylic, polyethylene and glass and broken and leaking vials.

Ongoing Sterility / contamination American Regent, Inc. NDC 0517-3030-01 D-0865-2026
Class II · Moderate risk

Maximum

Stability Data Does Not Support Expiry Date.

Ongoing Stability / shelf life HTO Nevada Inc. dba Kirkman D-0387-2026

Other recalls by Hospira Inc., A Pfizer Company

All 2017 recalls
Class II · Moderate risk

Labetalol Hydrochloride Injection

Defective Container: Cracked glass at the rim surface of glass vials, covered by the stopper and crimp seal.

Terminated Packaging defect Hospira Inc. A Pfizer Company NDC 0409-2267-20 D-0576-2018
Class III · Low risk

Argatroban Injection

Failed Impurities/Degradation Specifications; out of specification result for denitroquinoline-related impurity during three month time point

Terminated Impurity / degradation Hospira Inc., A Pfizer Company NDC 0409-1140-01 D-0980-2017